Earnings NewsHealthcareEndocyte Q3Nov. 07, 2018 4:07 PM ETEndocyte, Inc. (ECYT) StockBy: Douglas W. House, SA News Editor Endocyte (NASDAQ:ECYT) Q3 results ($M): Net loss: (23.3) ( -84.9%). Upcoming milestones: IND for Phase 1 study of EC17/CAR-T therapy in osteosarcoma (this quarter). Completion of merger with Novartis (NVS): H1 2019. Analysis of rPFS in VISION study: late 2019. Recommended For YouMore Trending NewsSee More »Related StocksSymbolLast Price% ChgECYT--Endocyte, Inc.Trending AnalysisTrending News